Senior Biopharma Executive Joins MMS Holdings as Principal Medical Director

CANTON, Mich.--(BUSINESS WIRE)--MMS Holdings, a data-focused contract research organization (CRO), announced the addition of Robert Allen, MD, to its team as Principal Medical Director of Global Drug Safety and Pharmacovigilance.

Bringing more than 20 years of pharmaceutical industry experience, Dr. Allen has worked at Parke Davis, Pfizer, Adolor, AstraZeneca, Wyeth, Scirex, Premier, and Inventive/Syneos. In recent years, he has served as Chief Medical Officer for several start-up companies, including Afferent, Centrexion and Concentric Pharmaceuticals. As CEO of Allen Medical, he also provided medical and regulatory support for sponsors globally on the design and execution of clinical studies and drug development plans.

Dr. Allen will act as senior technical reviewer for complex projects and provide sponsors with medical advice and regulatory support. Within our medical affairs group, he will provide expert guidance on safety surveillance, signal detection, risk evaluation, risk mitigation strategies, medical monitoring and more while supporting pharmacovigilance colleagues across MMS global operations.

“MMS is synonymous with quality and is a recognized industry leader in supporting clinical development plans all the way through regulatory submissions,” said Dr. Robert Allen. “I’m excited to bring my years of diverse drug development, safety, and regulatory experiences to support new and existing MMS clients, with a personal vision and set of goals to provide flawless execution of services, as we strive to bring life-changing therapies to patients around the world.”

“At MMS, our passion is helping clients bring new drugs to the market in a timely manner while upholding the utmost scientific rigor,” said Dr. Uma Sharma, Founder and Chief Scientific Officer of MMS Holdings. “With the addition of Dr. Allen to our Global Drug Safety and Pharmacovigilance team, we will continue to build on our portfolio of clients achieving drug approvals through our regulatory support and expertise. Besides, it will be great to work with Rob again after almost two decades.”

ABOUT MMS

MMS Holdings (MMS) is an innovative, data-focused CRO that supports the pharmaceutical, biotech, and medical device industries with a proven, scientific approach to complex trial data and regulatory submission challenges. Strong industry experience, technology-enabled services, and a data-driven approach to drug development make MMS a valuable CRO partner, creating compelling submissions that meet rigorous regulatory standards. With a global footprint across four continents, MMS maintains a 97 percent customer satisfaction rating.